Palvella Therapeutics (PVLA) EBITDA (2013 - 2026)
Palvella Therapeutics (PVLA) reported EBITDA of -$15.8 million for Q1 2026, down 92.35% year-over-year from -$205.8 million in Q1 2025, and down 23.71% quarter-over-quarter from -$12.7 million in Q4 2025.
Palvella Therapeutics (PVLA) EBITDA (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 14 years of EBITDA data on file, last reported at -$15.8 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$15.8 million, down 92.35% year-over-year; the trailing twelve-month figure through Mar 2026 was -$49.2 million (down 114.92% YoY), and the FY2025 annual result was -$41.6 million, down 138.86% from the prior year.
- EBITDA fell to -$15.8 million in Q1 2026 per PVLA's latest filing, from -$12.7 million in the prior quarter.
- Over five years, EBITDA peaked at $38.0 million in Q4 2023 and troughed at -$15.8 million in Q1 2026.
- A 5-year average of -$5.1 million and a median of -$8.9 million in 2025 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2025: EBITDA surged 139.99% in 2023, then slumped 278.34% in 2025.
- A 5-year view of EBITDA shows it stood at -$9.8 million in 2022, then jumped by 485.88% to $38.0 million in 2023, then plunged by 108.87% to -$3.4 million in 2024, then tumbled by 278.34% to -$12.7 million in 2025, then decreased by 23.71% to -$15.8 million in 2026.
- Business Quant data shows PVLA's EBITDA at -$15.8 million in Q1 2026, -$12.7 million in Q4 2025, and -$11.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | -15.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.76 Mn |
| Dec 31, 2025 | -12.74 Mn |
| Sep 30, 2025 | -11.13 Mn |
| Jun 30, 2025 | -9.58 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -3.37 Mn |
| Sep 30, 2024 | -6.97 Mn |
| Jun 30, 2024 | -4.37 Mn |
| Mar 31, 2024 | -2.73 Mn |
| Dec 31, 2023 | 37.96 Mn |
| Sep 30, 2023 | -10.95 Mn |
| Jun 30, 2023 | 4.27 Mn |
| Mar 31, 2023 | -13.36 Mn |
| Sep 30, 2022 | -9.84 Mn |
| Jun 30, 2022 | -10.67 Mn |
| Mar 31, 2022 | -4.98 Mn |
| Dec 31, 2021 | -9.32 Mn |
| Sep 30, 2021 | -16.15 Mn |
| Jun 30, 2021 | -15.46 Mn |
| Mar 31, 2021 | -3.68 Mn |